Kwame Zaire is a veteran in the manufacturing sector who has seen the industry evolve from traditional assembly lines to the sophisticated, tech-driven environments of today. With a deep focus on production management and quality assurance, he brings a unique perspective to the intersection of regulatory oversight and facility engineering. Today, we sit down with Kwame to discuss the FDA’s latest initiative to streamline domestic drug production through its PreCheck pilot program. This conversation explores how early regulatory engagement aims to transform facility readiness, the specific challenges facing contract manufacturers, and the strategic importance of building resilient pharmaceutical hubs across the United States. We will delve into the nuances of the two-phase approach designed to expedite facility evaluations and the operational hurdles that remain for an agency managing a complex, diverse cohort of applicants.
The FDA recently hand-picked seven specific companies to kick off its PreCheck pilot program, ranging from legacy pharmaceutical giants to specialized manufacturers. How does the inclusion of such a diverse group—stretching from API production in Indiana to gene therapy in North Carolina—signal a shift in how the government views manufacturing readiness?
The selection of these seven companies, winnowed down from a pool of more than 80 applicants, reflects a massive strategic pivot toward proactive collaboration rather than reactive inspection. By including Eli Lilly’s API site in Lebanon, Indiana, alongside gene therapy pioneers like Kriya Therapeutics in Durham, the FDA is signaling that “readiness” must be standardized across vastly different technological landscapes. You can feel the shift in the air; it’s no longer just about meeting a checklist at the finish line, but about weaving regulatory alignment into the very concrete and steel of a new facility. This diversity ensures that the program tests everything from high-volume small molecule production to the incredibly delicate, small-batch requirements of biotechnology drug substances for rare diseases. It’s a bold attempt to prove that a predictable regulatory pathway can exist for both a massive global player and a specialized startup.
The program operates through two distinct phases: facility readiness and application submission. From your experience in production management, what does this “enhanced engagement” look like on the ground, and how does it change the timeline for a facility that isn’t even fully operational yet?
In the facility readiness phase, the “enhanced engagement” takes the form of early technical guidance that essentially brings the FDA into the room while the paint is still wet. Companies submit facility-specific Drug Master Files, allowing regulators to audit the site’s logic and safety protocols years before a single commercial dose is ever produced. This moves the high-stakes manufacturing conversation off the “critical path,” which is a total game-changer for production managers who usually live in fear of a late-stage Complete Response Letter. By the time they reach the application submission phase, the facility-focused pre-submission meetings allow for inspections to happen much earlier in the review cycle. It’s about replacing the traditional, high-tension “gotcha” inspection with a continuous stream of feedback that ensures the facility is validated and ready to scale the moment the drug application is approved.
Among the seven selected, companies like Cellares and Fujifilm represent the contract manufacturing side of the industry. What unique hurdles do pure-play CDMOs face when trying to fit into a regulatory framework that seems traditionally geared toward internal product development?
The inclusion of Cellares and Fujifilm is particularly fascinating because the PreCheck framework still has several unresolved questions regarding how it applies to the outsourced manufacturing model. CDMOs operate as platforms for multiple sponsors, which adds a layer of complexity when you are trying to finalize a facility-specific Drug Master File that might eventually support dozens of different drug applications. Cellares, for instance, is the only cell therapy platform in the group, and they are betting that this early engagement will prove to their partners that manufacturing is no longer the primary risk standing between a therapy and the patient. However, the industry is still watching closely to see if the FDA can maintain this “predictable pathway” when a facility’s production schedule is dictated by third-party clients rather than an internal pipeline. It requires a level of transparency and data-sharing that hasn’t always been the norm in the competitive world of contract manufacturing.
We see a heavy concentration of these pilot sites in states like North Carolina, New York, and New Jersey. What is the significance of establishing these regional hubs for biotechnology drug substances and sterile injectables under this new pilot?
The geographic clustering we see in this pilot—with three facilities in North Carolina alone, including Fujifilm in Holly Springs and Kyowa Kirin in Sanford—is a calculated move to bolster domestic supply chains for critical medicines. By focusing on North Carolina for cell culture and gene therapy, and New York for sterile liquid products and protein therapeutics, the FDA is essentially supporting the creation of high-tech manufacturing corridors. Amneal’s site on Long Island, for example, will focus on small molecule sterile liquids for respiratory and ophthalmic diseases, which are vital for public health. These hubs create a concentrated pool of specialized labor and infrastructure, making it easier for the FDA to manage its oversight while also fulfilling the mandates of Executive Order 14293. There is a sense of national security at play here, ensuring that the production of life-saving treatments for oncology, hematology, and rare diseases remains firmly rooted on American soil.
Despite the optimism surrounding this initiative, there are concerns about the FDA’s own staffing levels and the ability to maintain consistency across such varied manufacturing environments. How do you assess the risk of “predictability” when the agency itself is facing workforce reductions?
This is the “elephant in the room” for many of us in production management; the program’s success hinges entirely on the FDA’s operational capacity to show up and provide that “enhanced engagement.” Launched in August 2025, the PreCheck program promises a high-touch experience, yet the agency has navigated broader workforce reductions over the past year that could lead to bottlenecks. If the FDA cannot provide consistent, timely technical guidance, the predictability that companies like Regeneron or Amneal are counting on will evaporate, leaving them stuck in a regulatory limbo. Maintaining a uniform standard across a cohort that includes both a massive biotech drug substance site in Saratoga Springs and a specialized AAV-based gene therapy facility is an enormous logistical feat. There is a real fear that if the agency is spread too thin, the “expedited facility evaluation” could become a slower, more frustrating process than the traditional route it was meant to replace.
What is your forecast for the PreCheck program and its impact on the future of American pharmaceutical manufacturing?
I expect that over the next three to five years, the PreCheck pilot will become the gold standard for how we build high-stakes manufacturing capacity in the U.S., effectively ending the era of the “blind” facility launch. We will likely see a significant decrease in the number of facilities that fail their initial pre-approval inspections, as the 7 companies in this initial cohort pave the way for a more collaborative relationship with regulators. However, the real test will be whether the FDA can scale this beyond the first 7 participants to handle the hundreds of other domestic facilities that need similar relief. If the agency can solve its staffing challenges, we are looking at a future where “Made in America” drugs are synonymous with the highest levels of regulatory readiness and supply chain resilience. This program isn’t just about faster approvals; it’s about creating a manufacturing ecosystem that is robust enough to handle the next generation of complex, life-saving therapies without the constant threat of facility-related delays.
